The immune cell content of each patient with PRAD is shown in Fig. 8A. The results revealed that the low-risk group samples had significantly higher levels of T-cell CD4 memory quiescent, dendritic cell (DC) quiescent, and mast cell quiescent and significantly lower levels of regulatory T cells (Tregs) compared to the high-risk group. The gene discussed is CD4; the disease is prostate adenocarcinoma.